ImmunityBio (IBRX) Gains from Investment Securities (2014 - 2026)

ImmunityBio (IBRX) has 9 years of Gains from Investment Securities data on file, last reported at $295.4 million in Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 65840.4% year-over-year to $295.4 million in Q1 2026; TTM through Mar 2026 was $245.9 million, a 1253.86% increase from a year earlier, with the FY2025 full-year figure at -$49.1 million, down 146.0% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $295.4 million, up from -$30.7 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for IBRX reached as high as $295.4 million in Q1 2026 and fell as low as -$31.3 million in Q3 2024.
• Historically, Gains from Investment Securities has averaged $18.6 million across 5 years, with a median of -$6.8 million in 2024.
• Across the five-year window, Gains from Investment Securities tumbled 10144.78% in 2022 and surged 65840.4% in 2026, its largest moves.
• Year by year, Gains from Investment Securities stood at -$13.5 million in 2022, then soared by 689.9% to $79.4 million in 2023, then sank by 112.26% to -$9.7 million in 2024, then slumped by 215.86% to -$30.7 million in 2025, then surged by 1060.91% to $295.4 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $295.4 million in Q1 2026, -$30.7 million in Q4 2025, and -$14.9 million in Q3 2025.